Early signal of activity from a phase 2 study of st101, a first-in-class peptide antagonist of ccaat/enhancer-binding protein. (c/ebp), in recurrent glioblastoma (gbm).
NEURO-ONCOLOGY(2022)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined